Pulmonx Corporation
6.85
-0.20 (-2.84%)
At close: Jan 14, 2025, 3:59 PM
6.84
-0.15%
After-hours Jan 14, 2025, 04:00 PM EST
undefined%
Bid 5.3
Market Cap 270.49M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.47
PE Ratio (ttm) -4.66
Forward PE n/a
Analyst Buy
Ask 10.87
Volume 226,873
Avg. Volume (20D) 231,109
Open 7.09
Previous Close 7.05
Day's Range 6.80 - 7.27
52-Week Range 5.46 - 14.84
Beta undefined

About LUNG

Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence...

Sector Healthcare
IPO Date Oct 1, 2020
Employees 279
Stock Exchange NASDAQ
Ticker Symbol LUNG

Analyst Forecast

According to 6 analyst ratings, the average rating for LUNG stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 75.18% from the latest price.

Buy 66.67%
Hold 33.33%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Pulmonx Corporation is scheduled to release its earnings on Feb 19, 2025, during market hours.
Analysts project revenue of $22.29M, reflecting a 15.62% YoY growth and earnings per share of -0.45, making a 25.00% increase YoY.
8 months ago · Source
+21.5%
Pulmonx shares are trading higher after the compan... Unlock content with Pro Subscription
8 months ago · Source
+1.45%
Pulmonx shares are trading higher after the company reported better-than-expected Q1 financial results.